Evidence map›Paper›PMID 17211454›Full record

ArticleBritish journal of pharmacology2007

Urotensin-II induces ear flushing in rats.

J-s Qi, R Schulingkamp, T J Parry, R Colburn, D Stone, B Haertlein, L K Minor, P Andrade-Gordon, B P Damiano

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in British journal of pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

J-s QiJohnson and Johnson Pharmaceutical Research and Development, Spring House, PA 19477-0776, USA.
R Schulingkamp
T J Parry
R Colburn
D Stone
B Haertlein
L K Minor
P Andrade-Gordon
B P Damiano
Johnson & Johnson (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeWhile investigating the effects of systemic urotensin II (U-II), a potent vasoactive peptide acting at the UT receptor, we observed ear pinna flushing after systemic administration to conscious rats. In the present study, U-II-induced ear flushing was quantified in terms of ear pinna temperature change and potential mechanisms were explored. EXPERIMENTAL APPROACH: U-II-induced ear flushing was quantified by measuring lateral ear pinna temperature changes and compared to that of calcitonin gene-related peptide (CGRP), a known cutaneous vasodilator. Further, the effects of a variety of pharmacological agents on U-II-induced ear flushing were explored. KEY

resultsSubcutaneous injection of U-II (9 microg kg(-1))produced localized ear pinna flushing with an onset of approximately 15 min, a duration of approximately 30 min and a maximal temperature change of 9 degrees C. In contrast, CGRP caused cutaneous flushing within multiple cutaneous beds including the ear pinna with a shorter onset and greater duration than U-II. A potent UT receptor antagonist, urantide, blocked U-II-induced ear flushing but did not affect CGRP-induced ear flushing. Pretreatment with indomethacin or L-Nomega-nitroarginine methylester (L-NAME) abolished U-II-induced ear flushing. Mecamylamine or propranolol did not affect this response to U-II. Direct intracerebroventricular injection studies suggested that the ear flushing response to U-II was not mediated directly by the CNS. CONCLUSION AND IMPLICATIONS: Our results suggest that U-II-induced ear flushing and temperature increase is mediated by peripheral activation of the UT receptor and involves prostaglandin- and nitric oxide-mediated vasodilation of small capillary beds in the rat ear pinna.

Indexed as

Adrenergic beta-AntagonistsAnimalsAnti-Inflammatory Agents, Non-SteroidalBody TemperatureCalcitonin Gene-Related PeptideEar, ExternalEnzyme InhibitorsFlushingIndomethacinInjections, SubcutaneousMaleMecamylamineNG-Nitroarginine Methyl EsterNicotinic AntagonistsNitric Oxide Synthase Type IIIPropranololAdrenergic beta-AntagonistsAnti-Inflammatory Agents, Non-SteroidalCalcitonin Gene-Related PeptideEnzyme InhibitorsIndomethacinMecamylamineNG-Nitroarginine Methyl EsterNicotinic AntagonistsNitric Oxide Synthase Type IIIPropranololurotensin IIUrotensinsVasodilator Agents

Identifiers

PMID17211454
PMCPMC2189721
OpenAlexW1517659779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.